Aging, Atherosclerosis, Cardiovascular Diseases, Coronary Artery Disease, Heart Failure, Inflammation, Myocardial Infarction
Conditions
Brief summary
The investigators of this study have found that after a heart attack, some heart cells rapidly age (become senescent) and release proteins that make the heart disease worse. The investigators of this study would like to check for these aged-cell proteins in participants who have coronary artery bypass graft (CABG) surgery after a recent heart attack or to treat more stable heart disease. The investigators will do this by taking blood samples and a sample of normally discarded heart tissue from each group of participants. This might help tell us who is at the highest risk of developing heart disease and how people recover from a heart attack.
Detailed description
The goal of this observational study is to compare the levels of aged-cell proteins in participants who have coronary artery bypass graft (CABG) surgery after a recent heart attack or to treat more stable heart disease. The main questions it aims to answer are: 1. To identify if there is an increased in aged-cell proteins in participants who have had a myocardial infarction and are having CABG surgery, compared to participants who are having CABG surgery for more stable heart disease. 2. To establish if levels of these aged-cell proteins can predict outcomes for these patients, and if they correlate with other markers of heart disease. The investigators will do this by taking blood samples and a sample of normally discarded heart tissue from each group of participants. This might help inform who is at the highest risk of developing heart disease and how patients recover from a heart attack.
Interventions
None listed
Sponsors
Study design
Eligibility
Inclusion criteria
* Male and female patients aged 40 to 80 years old undergoing coronary artery bypass graft surgery for myocardial infarction or for stable angina.
Exclusion criteria
* patients with ST-elevation myocardial infarction requiring coronary angioplasty * patients who have had previous cardiac surgery * patients who have evidence of ongoing heart failure, * a left ventricular ejection fraction of less than 30% * need for pre-operative mechanical cardiac support. * Individuals with pre-existing acute kidney injury * Sepsis * \>Stage 4 chronic kidney disease
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Increase in senescent myocardial cells and senescence-associated secretory phenotype (SASP). | From baseline to 6 weeks. | Blood samples taken to measure expression of a range of biomarkers. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Correlation of senescence and SASP with clinical outcomes | From baseline to 6 weeks | Measures include incidences of mortality, stroke, duration of inotrope and vasopressor administration and other markers of myocardial disease, including troponins. |
| Progression of chronic cardiovascular disease | baseline to 6 weeks | Progression of chronic cardiovascular disease will be determined using serum NT-proBNP at 6 weeks post surgery |
| Clinical outcomes post surgery | Baseline to 6 weeks | Clinical outcomes associated with poorer recovery from MI |
Countries
United Kingdom
Contacts
Newcastle University
South Tees Hospitals NHS Foundation Trust